新的研究发现,在某些病人中,化学切除结肠癌复发率减半。 New study finds atezolizumab with chemo cuts colon cancer recurrence by half in certain patients.

新的研究表明,在第3阶段结肠癌手术后,如果DNA不匹配的修补不力(dMMMR),将位于ezolizumab的免疫疗法药物添加到化疗中,仅与化疗相比,就可将癌症复发和死亡风险降低50%。 New research shows that adding the immunotherapy drug atezolizumab to chemotherapy after surgery for stage 3 colon cancer with deficient DNA mismatch repair (dMMR) can reduce the risk of cancer recurrence and death by 50% compared to chemotherapy alone. 包括712名病人的ATOMIC第3阶段试验显示,混合治疗的3年无病存活率为86.4%,而仅化疗就占76.6%。 The phase 3 ATOMIC trial, which included 712 patients, demonstrated a 3-year disease-free survival rate of 86.4% for the combination treatment versus 76.6% for chemotherapy alone. 研究人员计划建议这种结合,作为对某些结肠癌病人的新的标准治疗方法。 Researchers plan to recommend this combination as a new standard treatment for certain colon cancer patients.